Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

se of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib. The data will be presented by Dr. Jorge Cortes at 3:00 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Quizartinib Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Experience From The AML Pilot Trial:  This is the first presentation of quizartinib use in combination with chemotherapy in newly diagnosed older AML patients, testing the feasibility and dose which could be given sequentially following conventional chemotherapy in patients over the age of 60 years.  The data will be presented by Dr. Alan Burnett at 5:15 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Results of Phase 1 Study of Quizartinib In Combination with Induction and Consolidation Chemotherapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia:  This dose escalation study is the first to report data on quizartinib in combination with standard induction and consolidation chemotherapy in patients between the ages of 18 to 60-years with newly diagnosed AML, regardless of FLT3 status. The data will be presented by Dr. Jessica Altman at 5:30 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

A Phase I Study of Quizartinib in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML:  A Therapeutic Advances in Childhood Leukemia & Lymphoma Study:  This was the first clinical trial using quizartinib in children between the ages of 1 month and 21-years with relapsed/refractory AML or MLL-rearranged ALL.  The data will be presented by Dr. Todd Coope
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... patient care in critical areas, announced the closing of an ... warrants to purchase up to an aggregate 3,500,000 shares of ... and $.01 per warrant.  The warrants have a per share ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Safeguard Mezzanine Debt Facility; Support Profitable GrowthALISO VIEJO, Calif., ... (Nasdaq: CLRT ), a premier anatomic pathology ... the pharmaceutical industry, announced today that it has completed ... preferred stock with Oak Investment Partners ...
... May 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... American Society of Clinical Oncology (ASCO) Annual Meeting being ... related to our product candidates Stimuvax(R), PX-866 and PX-12 ... ASCO Web site, www.abstract.asco.org ., ...
... ATLANTA, May 18 /PRNewswire-Asia/ -- Global biomedical sciences ... the year 2008. This rides on,Singapore,s strong scientific ... in 2007. , The ... investment environment, as companies look to the fast ...
Cached Biology Technology:Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 2Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 3Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 4Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 5Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 6Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 2Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 3Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 2Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 3Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 4Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore 5
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces it has ... for the 2015 International CES debut of the Wocket™ ... will be at the NXT-ID booth January 6th and 7 ...
(Date:12/19/2014)... Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced the ... Apple/AuthenTec TMDR92 & Sapphire - Technology Report" report ... Following the acquisition of AuthenTec in ... the iPhone 5S. It is currently the only device ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Physicists, chemists and engineers at the University of Pennsylvania ... of patchy particles, using charged, self-assembling molecules that may ... and perhaps be used in small batteries that store ... electrical charges of calcium ions just like the ...
... retinal prosthesis and fetal tissue transplant, restored some vision ... at Neuroscience 2009, the annual meeting of the Society ... news on brain science and health, may lead to ... an engineered protein restored vision in an animal model ...
... researchers from the United States, Korea, and France has sequenced ... E. coli bacteria, one used to study evolution ... practical applications. The findings will help guide future research and ... classical research that is the foundation of our understanding of ...
Cached Biology News:Penn team uses self-assembly to make molecule-sized particles with patches of charge 2Experimental treatments restore partial vision to blind people 2Genomes of 2 popular research strains of E. coli sequenced 2Genomes of 2 popular research strains of E. coli sequenced 3
... FLUOstar OPTIMA is a fully automated ... life science labs in academia and ... measurement principles: Fluorescence Intensity ... Time-Resolved Fluorescence including DELFIATM ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
... Security ChemStation is a ... application for data acquisition, ... searching and reporting, addressing ... data security, integrity, and ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known mammal microRNAs ...
Biology Products: